This New Jersey-Based Company Had One Of The Largest Pasta Recalls In The US
The November recall affected over 2,300 cases of ricotta-stuffed shells and stuffed shells with sauce and mozzarella distributed in six states: Arizona, California, Delaware, Indiana, Minnesota, and New Jersey. Both products may have been contaminated with listeria, a foodborne bacteria that can cause fever, chills, nausea, and diarrhea in otherwise healthy people. For young children, older individuals, and those with weakened immune systems, even more severe illnesses or death can result from infection.
Although the recall was voluntary, the seriousness of the potential consequences led Joseph Epstein Food Enterprises to pull these products from circulation. Nevertheless, the risk was low as indicated by the FDA's Class II designation for the action. Class II recalls are less severe than Class I designations, but in the FDA's words, there's "still the possibility of serious enough adverse events to have irreversible consequences."
Read more: 14 Canned Tomato Brands, Ranked Worst To Best
This combination of active prevention and lower danger led to no reports of injuries or illnesses linked to the pasta. As Mama Mancini's told Newsweek, "All affected product was quarantined and recalled before it was distributed to end consumers." The recall was terminated in late March 2025. Despite this, it remains high on the list of the biggest pasta recalls in U.S. history.
This was not the first recall to strike Joseph Epstein Food Enterprises. In 2015, the company's Mama Mancini's gluten-free turkey meatballs and Mama Mancini's Slow Cooked Italian Style Sauce were recalled after testing revealed they contained more than the allowable amount of gluten, making them potentially dangerous to people (such as those with celiac disease) following gluten-free diets. Fortunately, that recall only affected 190 pounds of food and didn't result in any illnesses.
It's understandable that recalls may be concerning to grocery shoppers and restaurant diners, especially when they involve a potentially harmful pathogen like listeria. However, with no adverse health effects and a quick resolution, it's also easy to see the recall as evidence of a food safety system working as intended.
Read the original article on Mashed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline
We recently published . MannKind Corporation (NASDAQ:MNKD) is one of the best healthcare stocks. MannKind Corporation (NASDAQ:MNKD)'s most recent milestone is its push to expand the use of its rapid-acting inhaled insulin, Afrezza, to pediatric patients. In August 2025, the company submitted a supplemental Biologics License Application to the FDA for use in children ages 4–17, supported by positive Phase 3 INHALE-1 trial results presented at major diabetes conferences. A regulatory decision is expected in Q4 2025. Clinical data from both pediatric (INHALE-1) and adult (INHALE-3) studies have reinforced Afrezza's efficacy and safety across age groups. These advances have also helped the business gain attention among investors looking at the best healthcare stocks. Beyond Afrezza, MannKind Corporation (NASDAQ:MNKD) is advancing its pipeline in respiratory and rare diseases. MNKD-101, an inhaled clofazimine for nontuberculous mycobacterial lung disease, is progressing ahead of schedule in its global Phase 3 ICoN-1 trial. MNKD-201, a therapy for idiopathic pulmonary fibrosis, is set to enter Phase 2 testing by the end of 2025. Copyright: nicoletaionescu / 123RF Stock Photo To support these initiatives, the business secured up to $500 million in non-dilutive financing from Blackstone in August 2025. This funding will accelerate the potential launch of pediatric Afrezza, expand its commercial capabilities, and advance its clinical programs. Together, these developments position MannKind Corporation (NASDAQ:MNKD) for growth in both diabetes care and specialty lung disease markets. While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
an hour ago
- Yahoo
ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates
We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best healthcare stocks. ImmunityBio, Inc. (NASDAQ:IBRX) is among the best healthcare stocks. It is a clinical-stage biotech company developing advanced immunotherapies and vaccines targeting cancers and infectious diseases by activating immune cells such as natural killer and T cells. A key recent milestone is the FDA-approved immunotherapy drug ANKTIVA for bladder cancer, specifically for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS). ANKTIVA, designated a Breakthrough Therapy, is expanding its clinical use, notably with the Michael E. DeBakey VA Medical Center in Houston becoming one of the first VA hospitals to administer the treatment to veterans, a population at higher bladder cancer risk. In Q2 2025, ImmunityBio, Inc. (NASDAQ:IBRX) reported a 60% revenue growth quarter-over-quarter, reaching $26.4 million and a year-to-date total of approximately $43 million. This growth is driven by increased commercial momentum post-approval and supported by an $80 million capital raise in July 2025 to fuel ongoing development and expansion. ImmunityBio, Inc. (NASDAQ:IBRX) is transitioning from a clinical-stage biotech to a commercial-stage company with ANKTIVA's expanding adoption, including recent UK regulatory approval for ANKTIVA plus BCG. The drug addresses an underserved cancer indication with the potential to reduce invasive treatments like cystectomy, backed by clinical data showing durable bladder preservation up to 36 months in responders. While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
Trump administration tiptoes into testing prior authorization in traditional Medicare
Traditional Medicare plan holders have typically not had to wait for prior authorization before receiving medical treatment. Until now. The Centers for Medicare & Medicaid Services (CMS) recently announced a new program to test prior authorization requirements for certain services in six states starting Jan. 1. The states — New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington — will apply prior authorization evaluations to more than a dozen services. CMS says the pilot program is intended to root out 'fraud, waste, and abuse,' but as Medicare Advantage members know well, prior authorization can lead to frustrating delays in care. How it works CMS will contract with private companies to deploy 'enhanced technologies, including artificial intelligence (AI)' to conduct the authorization reviews. It won't apply to in-patient or emergency services or treatments 'that would pose a substantial risk to patients if significantly delayed,' according to a CMS press release. Specific services that will require prior authorization are skin and tissue substitutes, electrical nerve stimulator implants, and knee arthroscopy. There is genuine concern about the costs of some of these items and services. A recent New York Times article highlighted pricey medical products, including paper-thin bandages made of dried bits of placenta, for Medicare patients. The Biden administration had approved a plan to limit Medicare's coverage of the bandages, known as skin substitutes, which were reportedly being sold for roughly $10,000 per square inch. An updated Medicare policy proposes setting a significantly lower payment rate. The new prior authorization program 'is focused on reducing wasteful spending, which is an important goal for Medicare,' Jeffrey Marr, a health economist at the Brown University School of Public Health, told Yahoo Finance. 'I expect that the use of prior authorization in this model is likely to reduce the overall level of Medicare spending,' he said. 'Selecting potentially low-value services is a critical part of setting up a well-functioning prior authorization system.' The key question for CMS to address is whether prior authorization can work in traditional Medicare in a way that does not deny or discourage high-value care that improves beneficiaries' health, Marr said. One red flag: 'The companies that will make the prior authorization decisions will be paid a percentage of the savings that they generate for Medicare. This creates an incentive for participants to deny a high share of services,' he said. Sign up for the Mind Your Money weekly newsletter By subscribing, you are agreeing to Yahoo's Terms and Privacy Policy Prior authorizations are part of the Medicare landscape How often do prior authorizations pop up for seniors with Medicare and Medicare Advantage plans? In traditional Medicare, services that often require prior authorization include certain outpatient hospital services, non-emergency ambulance transport, and durable medical equipment. For 2023, under 400,000 prior authorization reviews for traditional Medicare beneficiaries were submitted to CMS, according to KFF data. Medicare Advantage plans, which are offered by private insurers, are a different story. Almost all Medicare Advantage enrollees — 99% according to KFF research — must receive prior authorization for some services. These are typically higher-cost services, such as inpatient hospital stays, skilled nursing facility stays, chemotherapy, and other drugs. That common practice, combined with AI used to scan these requests, is a thorny issue. 'Prior authorization processes and requirements, including the use of artificial intelligence to review requests, may result in administrative hassles for providers, delays for patients in receiving necessary care, and in some instances, denials of medically necessary services, such as post-acute care,' according to Jeannie Fuglesten Biniek, co-author of the KFF report. To allay that fear, CMS noted in the announcement: 'While technology will support the review process, final decisions that a request for one of the selected services does not meet Medicare coverage requirements will be made by licensed clinicians, not machines.' The prior authorization program will not alter Medicare coverage or payment rules, for now, but other services may be added later. There has been pushback. More than a dozen members of Congress sent a letter on Aug. 7 to CMS administrator Dr. Memet Oz to urge him to 'put patients and providers first by cancelling' the model and requested more details about how the program will be implemented. 'The use of prior authorization in Medicare Advantage shows us that, in practice, [this proposal] will likely limit beneficiaries' access to care, increase burden on our already overburdened healthcare workforce, and create perverse incentives to put profit over patients,' the lawmakers wrote.A pivot in MA authorization In an odd juxtaposition, a week prior to trumpeting this new Medicare pre-authorization model, the administration announced that it had a non-binding commitment from insurance plans to reduce prior authorization in Medicare Advantage. In late June, the Department of Health and Human Services announced an initiative coordinated with companies including Aetna, Blue Cross Blue Shield, Humana, and UnitedHealthcare, to streamline prior authorization processes for patients covered by Medicare Advantage. Under the initiative, electronic prior authorization requests would become standardized by 2027. 'Pitting patients and their doctors against massive companies was not good for anyone,' US Health and Human Services Secretary Robert F. Kennedy, Jr. said in a statement. 'We are actively working with industry to make it easier to get prior authorization for common services such as diagnostic imaging, physical therapy, and outpatient surgery.' Oz added: 'These commitments represent a step in the right direction toward restoring trust, easing burdens on providers, and helping patients receive timely, evidence-based care.' Kerry Hannon is a Senior Columnist at Yahoo Finance. She is a career and retirement strategist and the author of 14 books, including the forthcoming "Retirement Bites: A Gen X Guide to Securing Your Financial Future," "In Control at 50+: How to Succeed in the New World of Work," and "Never Too Old to Get Rich." Follow her on Bluesky. Sign up for the Mind Your Money newsletter
